KalVista Pharmaceuticals Maintains Buy Rating with $28 Price Target Amidst Promising Ekterly Launch and Strong Financial Position

KalVista Pharmaceuticals has been given a Buy rating by analyst Serge Belanger due to the FDA approval of Ekterly and the company's strong financial position. The launch of Ekterly is expected to begin soon, giving it a head-start in the oral on-demand treatments for hereditary angioedema market. The company's robust cash position is projected to support the launch and sustain operations into FY27. Belanger predicts peak sales of $700 million, justifying the positive recommendation and a price target of $28.

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) has received a significant boost with the FDA approval of EKTERLY® (sebetralstat), a novel plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adults and children aged 12 and older. This approval marks the first and only oral on-demand treatment for HAE, offering a significant advancement in the management of this rare genetic disease.

The FDA approval was announced on July 7, 2025, following the successful completion of the phase 3 KONFIDENT clinical trial, which demonstrated rapid symptom relief and attack resolution, regardless of attack severity, location, age, or use of long-term prophylaxis. The trial, the largest conducted in HAE, randomized 136 patients from 66 clinical sites across 20 countries and showed that EKTERLY achieved significantly faster symptom relief and attack resolution compared to placebo [1].

Analyst Serge Belanger has upgraded KalVista's stock to a "Buy" rating, citing the FDA approval and the company's strong financial position. Belanger predicts peak sales of $700 million, driven by the launch of EKTERLY, which is expected to begin soon. The analyst also projects that the company's robust cash position will support the launch and sustain operations into FY27, justifying the positive recommendation and a price target of $28 [2].

KalVista's CEO, Ben Palleiko, expressed gratitude for the FDA approval, stating, "EKTERLY enables people to treat attacks the moment symptoms begin, wherever they are. This approval affirms the strength of our science and deep commitment to the HAE community." The company is committed to delivering EKTERLY to those in need, having established the KalVista Cares™ patient support program to assist with insurance coverage and ongoing treatment support [1].

The approval of EKTERLY represents a milestone in the treatment of HAE, offering patients and physicians an important new option for managing attacks. The oral on-demand therapy provides greater independence and control, potentially reducing the overall burden of the disease [1].

KalVista will host a conference call and webcast today, July 7, 2025, at 8:30 a.m. ET, to discuss the FDA approval of EKTERLY. For more information, visit ir.kalvista.com.

References:
[1] https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-fda-approval-ekterly
[2] https://example.com/analyst-reports